Segment (Tables)

Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):


	Three Months Ended March 31,
		2026		2025
Revenue:
Testing revenue		$	135,091	$	107,309
Product revenue		3,679		3,580
Biopharmaceutical and other revenue		301		3,584
Total revenue		139,071		114,473
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense		12,314		13,067
Sample collection expense		3,288		2,825
Compensation expense		9,804		5,611
Other cost of testing revenue (1)		4,937		3,385
Allocation of facilities and IT expenses		2,963		3,372
Total cost of testing revenue		33,306		28,260
Cost of product revenue:
Product costs		1,401		109
License fees and royalties		313		324
Other cost of product revenue (2)		174		792
Allocation of facilities and IT expenses		3		197
Total cost of product revenue		1,891		1,422
Cost of biopharmaceutical and other revenue:
Compensation expense		—		1,240
Other cost of biopharmaceutical and other revenue (3)		8		1,044
Allocation of facilities and IT expenses		—		414
Total cost of biopharmaceutical and other revenue		8		2,698
Intangible asset amortization - cost of revenue		2,707		2,585
Gross profit		101,159		79,508
Operating expenses:
Research and development:
Compensation expense		15,547		9,748
Direct research and development expense		4,198		4,141
Other research and development expenses (4)		5,460		1,815
Allocation of facilities and IT expenses		1,893		2,016
Total research and development		27,098		17,720
Selling and marketing:
Compensation expense		19,972		17,635
Direct marketing expense		1,455		710
Other selling and marketing expenses (5)		4,561		3,853
Allocation of facilities and IT expenses		1,168		2,256
Total selling and marketing		27,156		24,454
General and administrative:
Compensation expense		16,236		20,173
Other general and administrative expenses (6)		13,471		21,890
Allocation of facilities and IT expenses		(6,027)		(8,255)
Total general and administrative		23,680		33,808

Intangible asset amortization - operating expenses		579		622
Other income, net		(7,328)		(4,524)
Income tax provision		1,267		381
Net income		$	28,707	$	7,047

(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.

(2)Other cost of product revenue includes contract manufacturing fees, license fees and royalties, depreciation and amortization and other expenses.

(3)Other cost of biopharmaceutical and other revenue includes professional fees, information technology expense, depreciation and amortization and other expenses.

(4)Other research and development expenses include depreciation and amortization and other expenses.

(5)Other selling and marketing expenses include travel, entertainment, conference and other expenses.

(6)Other general and administrative expenses include professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.